Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Short-Term Debt issuances (2018 - 2025)

Amphastar Pharmaceuticals has reported Short-Term Debt issuances over the past 7 years, most recently at $273000.0 for Q4 2025.

  • Quarterly results put Short-Term Debt issuances at $273000.0 for Q4 2025, down 94.39% from a year ago — trailing twelve months through Dec 2025 was $6.2 million (down 66.28% YoY), and the annual figure for FY2025 was $6.2 million, down 66.28%.
  • Short-Term Debt issuances for Q4 2025 was $273000.0 at Amphastar Pharmaceuticals, up from $172000.0 in the prior quarter.
  • Over the last five years, Short-Term Debt issuances for AMPH hit a ceiling of $500.0 million in Q2 2023 and a floor of -$25000.0 in Q2 2024.
  • Median Short-Term Debt issuances over the past 3 years was $4.1 million (2024), compared with a mean of $58.3 million.
  • Biggest five-year swings in Short-Term Debt issuances: plummeted 100.0% in 2024 and later soared 16616.0% in 2025.
  • Amphastar Pharmaceuticals' Short-Term Debt issuances stood at $500.0 million in 2023, then plummeted by 99.03% to $4.9 million in 2024, then crashed by 94.39% to $273000.0 in 2025.
  • The last three reported values for Short-Term Debt issuances were $273000.0 (Q4 2025), $172000.0 (Q3 2025), and $4.1 million (Q2 2025) per Business Quant data.